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functional capacity, but only with minimum clinically impor-
tant differences, in the ETG group.
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Understanding symptoms variability
in outpatients with AECOPD
Dear Editor,
Symptoms are the cornerstone for diagnosing acute exacer-
bations of chronic obstructive pulmonary disease (AECOPD),
however little information is available on their variability
during these events and on their relationships with objective
clinical measures. This study explored changes in patients’
symptoms and their relationships with objective clinical
measures during AECOPD.
Methods
A longitudinal observational study was conducted with
thirty-six outpatients with AECOPD (24 males; 68.4±9.9
years; forced expiratory volume in one second (FEV1)
50.7±20.4%predicted) recruited from the urgent care of
a Central hospital. Patients attended to 4 assessments:
until 48 hours of the urgent care visit (T1), 8 days
(T2), 15 days (T3) and 45 days (T4) after the hospital
visit. Patients’ prescriptions included only pharmacologi-
cal treatment and consisted in antibiotics (n=16; 44.4%),
beta-adrenergic agonists (n=2; 5.6%), cholinergic antag-
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onists (n=3; 8.3%), associations of bronchodilators with
cholinergic antagonists (n=7; 19.4%), anti-inﬂammatory
drugs (n=1; 2.8%), xanthines (n=1; 2.8%) and expectorants
(n=6; 16.7%).
Activities-related dyspnoea (modiﬁed British Medi-
cal Research Council questionnaire -- mMRC), dyspnoea
and fatigue at rest (modiﬁed Borg Scale -- MBS),
cough, sputum and wheezing symptoms (11-point numer-
ical scale) were registered in each assessment. FEV1,
using a portable spirometer, and quadriceps muscle
strength (QMS), using a handheld dynamometer, were also
collected.
The number of participants presenting symptoms, the
severity of symptoms, FEV1 and QMS were compared among
T1, T2, T3 and T4 using the Cochran or Friedman tests,
respectively. Changes in symptoms were correlated with
changes in FEV1 and QMS using the Spearman’s correlation
coefﬁcient.
Results
Dyspnoea and cough were the most reported symptoms at
the onset of AECOPD. The number of patients with dyspnoea
at rest, assessed with the MBS (MBS>0), decreased signif-
icantly from T1 to T4 (22 vs. 16 vs. 15 vs. 13; p=0.040)
(Table 1). No signiﬁcant differences were observed in the
number of patients presenting activities-related dyspnoea,
fatigue at rest, cough, sputum and wheezing symptoms. Dur-
ing the time course of the AECOPD, participants presented
signiﬁcantly more i) activities-related dyspnoea in T1, than
in T3 (p=0.001) and T4 (p=0.028); ii) dyspnoea at rest in T1
than in T4 (p=0.016); iii) cough in T1 than in T2 (p=0.001),
T3 (p<0.001) and T4 (p<0.001) and iii) wheezing in T1 than
in T4 (p=0.022) (Table 1).
Changes occurring between T1 and T3 in mMRC cor-
related inversely with changes in QMS (rs=-0.41; p=0.013)
whilst changes in cough (rs=0.47; p=0.021) correlated
positively with QMS. Changes in MBS -- dyspnoea (rs=-
0.47; p=0.004) and fatigue (rs=-0.34; p=0.046) correlated
inversely with changes in FEV1 (Fig. 1). No further corre-
lations were found.
Discussion
Dyspnoea and cough were the most reported symptoms at
the onset of AECOPD.1,2 Dyspnoea was the most prevalent
symptom. Its time-recovery matched previous reports (i.e,
6 to 30 days).1,2 Cough was the symptom reported with the
highest severity and the ﬁrst to improve after treatment
initiation. In COPD cough is the most common symptom for
which individuals seek medical attention and is a cardinal
symptom in upper tract infections,3 one of the most common
causes of AECOPD. Our results support the need of increasing
awareness about cough severity and behaviour. Recognising
the cough pattern may aid to guide patients’ monitoring and
interventions, reduce need for hospitalisation, recurrence
of AECOPD and, consequently, costs and morbidity related
with these events.
Differences in wheezing were only detected 45 days after
the onset of the exacerbation, which differs from previ-
ous reports using computerised respiratory sound analysis
(i.e., improvements 15 days after the AECOPD).4 Lack of
agreement between subjective and objective measures have
already been reported for other outcomes, such as cough,5
and highlights the need for incorporating both patient-
reported and clinical outcome measures in the assessment
of patients with AECOPD.
Similar to other studies, associations between improve-
ments in dyspnoea and higher expiratory ﬂow rates were
found, possibly due to the inﬂammatory aetiology of the
acute exacerbation itself (i.e., reduction in inﬂamma-
tion during recovery from the AECOPD may inﬂuence the
reduction of dyspnoea and increase expiratory ﬂow rates)
and/or reductions in lung hyperinﬂation.2 Nevertheless,
both inﬂammation and hyperinﬂation were not directly
studied in the present research and thus interpretations
should be made carefully. A relationship between dyspnoea
and QMS was also found, as previously reported in stable
patients with COPD, due to the ‘‘downward disease spi-
ral’’ of increased dyspnoea, decreased physical activity and
deconditioning of locomotor muscles.6 During AECOPD, this
downward spiral may be even more prominent as patients
severely decrease their activities.
The positive correlation found between changes in cough
severity and QMS was unexpected. Whilst cough severity
showed signiﬁcant improvements at day 15 of the AECOPD,
QMS remained statistically unchanged during the same
period, with 36% of the patients exhibiting decreases in
their QMS. Similar results have been found in hospitalised
patients, where QMS decreased during the ﬁrst 8 days of hos-
pitalisation for AECOPD and only recovered at day 90.7 Thus,
although both outcomes improved during an AECOPD, their
timing of improvement differs, which may explain the pos-
itive correlation found between changes at T3-T1 between
these two outcomes. Studies describing the pattern of QMS
recovery in outpatients with AECOPD are needed to con-
ﬁrm these results and aid developing timely and personalised
interventions.
Despite the novel ﬁndings in symptoms behaviour during
AECOPD, this study has some limitations that need to be
acknowledged. Treatment of exacerbations was not stan-
dardised, but rather prescribed according to the physician
best judgment. Although the effects of therapies were not
of interest in this study, it must be acknowledged that
different combination of treatments might inﬂuence the
recovery times and outcomes of individual patients. Char-
acterisation of symptoms lack other important features,
such as sputum purulence. These data can contribute to
infer about the nature of the AECOPD (i.e., infective - viral
and/or bacterial - or non-infective) and about the suitabil-
ity of treatments prescribed. It is thus recommended to
add sputum purulence to data collection in future study
protocols.
In sum, this study showed that: i) dyspnoea is the most
representative symptom at the onset of an AECOPD; ii)
severity of cough is the ﬁrst symptom to improve during
the course of an AECOPD, and iii) changes in symptoms
were correlated with FEV1 and QMS, which are predictors
of COPD hospitalisations and mortality. Our ﬁndings evi-
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Table 1 Clinical variables and symptoms variability during the course of an AECOPD.
AECOPD (T1) 8 days (T2) 15 days (T3) 45 days (T4) p-value
FEV1, L 0.9 [0.7-1.4] 0.9 [0.7-1.3] 1.1 [0.7-1.6] 1.2 [0.8-1.6] 0.075
QMS, kgf 12.2
[9.2-20.1]
13.9
[10.9-18.6]
13.2
[11.2-21.8]
17.8*
[13.3-24.7]
p<0.001
No. patients (mMRC>0) 35 31 32 30 0.091
mMRC 2.0 [2.0-3.0] 2.0 [2.0-2.8] 2.0 [1.0-2.0]* 1.5 [1.0-2.0]* p<0.001
No. patients (MBS.d>0) 22 16 15 13* 0.040
MBS - dyspnoea 3.0 [0.0-4.0] 0.0 [0.0-2.8] 0.0 [0.0-2.8] 0.0 [0.0-1.8]* p=0.001
No. patients (MBS.f>0) 17 15 17 11 0.249
MBS - fatigue 0.0 [0.0-3.0] 0.0 [0.0-3.0] 0.0 [0.0-3.0] 0.0 [0.0-2.0] p=0.001
No. patients (NS.cough>0) 24 23 21 23 0.056
Cough 8.0 [6.0-10.0] 4.0[2.0-5.0]* 3.0 [2.0-5.0]* 2.0 [0.0-4.0]* p<0.001
No. patients (NS.sputum>0) 22 23 21 24 0.392
Sputum 5.0 [2.0-7.5] 3.0 [1.5-6.0] 3.0 [2.0-4.0] 2.0 [0.5-5.0] p=0.061
No. patients (NS.wheezeing>0) 20 21 17 19 0.183
Wheezing 6.0 [2.5-10.0] 4.0 [1.0-8.0] 3.0 [0.0-5.5] 2.0 [0.0-4.0]* p=0.006
Legend: Values are shown as number or median [interquartile range]; signiﬁcant difference at p<0.05; * different from T1.
FEV1, forced expiratory volume in one second; mMRC, modiﬁed British Medical Research Council questionnaire; MBS.d, modiﬁed Borg
scale -- dyspnoea; MBS.f, modiﬁed Borg scale -- fatigue; NS, numerical scale; QMS, quadriceps muscle strength.
Figure 1 Correlations between changes from T1 to T3 in A) modiﬁed Borg scale -- dyspnoea (MBS.d) and forced expiratory volume
in 1 second (FEV1); B) modiﬁed Borg scale -- fatigue (MBS.f) and FEV1; C) modiﬁed British Medical Research Council questionnaire
(mMRC) and quadriceps muscle strength (QMS); D) Cough, assessed with the numerical scale, and QMS.
dence that timely management of symptoms is essential for
patients’ recovery and should encourage health profession-
als to perform a comprehensive evaluation of outpatients
with AECOPD using both patients reported symptoms and
objective clinical outcome measures.
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